ALKS - Wutah dodolan YoY (TTM) Alkermes plc

Tandha merek Alkermes plc (ALKS)

Alkermes plc net profit is based on the development of innovative psychiatric therapies and the implementation of extended-release drug delivery systems. Year-over-year sales dynamics over the last four quarters visualize this process, where the 15.40 indicator expresses the state of the metric. Stability is guaranteed by the neutral geopolitical status of the Irish business, while primary revenues are generated by complex injections for patients with schizophrenia and addictions.

ALKS (Alkermes) riwayat Wutah dodolan YoY sajrone rolas wulan kepungkur saka 11.02.2024 nganti 17.11.2026

Ringkesan rincian data analitis Alkermes (ALKS)

- nilai pasar lan prakiraan target analis:
Analisis kabeh metrik perusahaan:ALKS - Alkermes Inc.
Produk asil prodhuksi alkermes.com

Alkermes plc specializes in developing treatments for mental health disorders and addictions. This metric captures the trend of total revenue over the last twelve months relative to the previous year. By analyzing the trailing twelve-month (TTM) sales growth, an investor tracks the effectiveness of the company's patent strategy and licensing streams. Steady growth here confirms the expansion of Alkermes plc in the global neuropharmaceutical market, signaling the fundamental resilience of the business.